Double-tract vs tubular gastric reconstruction after proximal gastric cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This analysis looks at patients with proximal gastric cancer who underwent either double-tract reconstruction or tubular gastric anastomosis. The study collects data from six tertiary hospitals, using medical records, follow-up endoscopy, 24-hour pH monitoring, and various clinical scales to compare postoperative outcomes. It is an observational comparison of two surgical approaches rather than a randomized trial. Results may inform which reconstruction method offers better postoperative quality of life and symptom control. Lead sites include Qilu Hospital of Shandong University in Jinan, Shandong.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathologically confirmed gastric adenocarcinoma by biopsy
* Carcinoma of the upper gastric body or Siewert type II/III adenocarcinoma of the esophagogastric junction (AEG), with a clinical stage of cT1-3N0-1M0
* Age 18-75 years, with a performance status (PS) score of 0-2
* Candidates for planned surgical resection, eligible for either double-tract reconstruction or tubular gastric anastomosis based on preoperative assessment
* No severe dysfunction of vital organs (liver, kidney, heart, lung, or brain), and no severe infection or uncontrolled chronic diseases

Exclusion Criteria:

* Presence of other malignant tumors or severe chronic diseases (e.g., severe diabetes mellitus, chronic kidney disease, decompensated cirrhosis, etc.)
* Preoperative endoscopic diagnosis of Barrett's esophagus
* Severe preoperative malnutrition (albumin \<30 g/L, prealbumin \<150 mg/L)
* History of prior upper abdominal surgery, gastrointestinal malformation, or psychiatric disorders
* Preoperative diagnosis of obstructive motor disorders of the cardia (including achalasia spectrum disorders)
* Inability to cooperate with or complete the required postoperative examinations

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Hui Qu, Doctor of Medicine
• Email: doctorquhui@email.sdu.edu.cn
• Phone: +8618560085120

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery

  A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.

  Recruiting at 8 sites The Affiliated Hospital of Qingdao University · Qingdao, Shandong and 7 other locations · NCT07898293

• Anti-PD-1 with chemotherapy and intraperitoneal nab-paclitaxel for untreated advanced gastric cancer with ascites

  This study tests whether adding anti-PD-1 therapy to standard chemotherapy plus intraperitoneal nab-paclitaxel can help patients with untreated advanced gastric cancer and malignant ascites.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07855640

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Multimodal Prehabilitation for Gastric Cancer Patients

  This program tests whether a combined pre- and post-operative wellness plan can reduce inflammation after gastric cancer surgery in adults.

  Recruiting National University Hospital, Singapore · Singapore · NCT07839702

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.